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Abstract
Background/Aims: Apparent treatment resistant hypertension (aTRH) is highly prevalent in 
patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The impact of aTRH and 
achievement of recommended blood pressure (BP) values on the rate of glomerular filtration 
rate (eGFR) loss in CKD patients is poorly known. To assess the role of aTRH and time-updated 
BP control (BPC) on the progression of CKD in patients with T2D and hypertension (HT) in 
real life clinical practice. Methods: Clinical records from a total of 2,778 diabetic patients with 
HT and stage 3 CKD (i.e. baseline eGFR values between 30 and 60 ml/min) and regular visits 
during a four-year follow-up were analyzed. The association between BPC (i.e. 75% of visits 
with BP <140/90 mmHg) and eGFR loss (i.e. a >30% reduction from baseline) or worsening of 
albuminuria status over time was assessed. Results: At baseline 33% of patients had aTRH. Over 
the 4-year follow-up, 20% had a >30% eGFR reduction. Patients with aTRH had an increased 
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risk of eGFR loss >30% (OR 1.31; P<0.007). In patients with aTRH, BPC was associated with a 
79% (P=0.029) greater risk of eGFR reduction despite a 58% (P=0.001) lower risk of albuminuria 
status worsening. In non-aTRH, no association was found between BPC and renal outcome. 
Conclusion: In patients with stage 3 CKD the presence of aTRH entails a faster loss of eGFR. 
More effective prevention of aTRH should be implemented as this condition is associated with 
a burden of risk not modifiable by tight BP reduction.
Introduction
Resistant hypertension (RH), defined as a blood pressure (BP) above recommended 
levels despite optimal combination of at least three different drugs including a diuretic [1-
3], is a relatively frequent finding in patients at cardiovascular risk (CVR), especially in the 
presence of diabetes and chronic kidney disease (CKD) [4-6]. The prevalence of RH has been 
reported to vary considerably, from 10 to 40% [3, 7], depending on the clinical setting and 
confounding factors such as poor adherence to treatment. Thus, it has been suggested that 
the term apparent treatment resistant hypertension (aTRH) should be used when adherence 
to medications or out-of-office BP cannot be verified [8].
ATRH has been associated to worse cardiovascular (CV) morbidity and mortality [9-
10] and accelerated loss of renal function in CKD patients [6, 11]. In a recent retrospective 
study conducted on a large general population cohort, the presence of RH was associated 
with a 23% greater risk of developing a cardiovascular event as well as a 25% greater risk 
of reaching end-stage renal disease (ESRD). These data further strengthen the association 
between severity of hypertension and unfavorable vascular outcome and underscore the 
importance of early identification and possibly prevention of RH [12].
Moreover, and somewhat surprisingly, preliminary studies seem to indicate that 
pharmacologic reduction of BP does not provide much cardiovascular and renal protection 
in RH [9, 13-14] and may even be associated with harm [3]. As a matter of fact, in a recent 
retrospective study on a large cohort of treated hypertensive patients in the US, very low 
on-treatment BP values (i.e. SBP<120 and/or DBP<70 mmHg) were associated with greater 
cardiovascular risk as compared to more relaxed BP control independently of the presence 
of aTRH [15]. Likewise, in a post-hoc analysis of Ontarget /Transcend studies, mean achieved 
SBP below120 mmHg was associated with an increase in CV and all cause death [16].
Taken together, these data support the possibility of a paradoxical increase in 
cardiovascular and renal risk when BP is reduced to very low values. This so called J-curve 
phenomenon has especially been reported in highly comorbid patients such as those with 
aTRH.
No study so far has evaluated long term renal outcome, under real life clinical conditions, 
in patients with aTRH, type 2 diabetes (T2D) and CKD. We therefore set out to investigate the 
relationship between the presence of aTRH, achievement and maintenance of recommended 
BP values and changes in eGFR and albuminuria over a 4-year period in a large cohort of 
patients with T2D, hypertension and CKD in Italy.
Materials and Methods
Study participants
As already reported [17-19], in Italy, diabetes care is mostly provided by a public network of about 700 
diabetes clinics in which a team of specialists provides diagnostic confirmation, prevention and treatment 
for diabetes and its complications through close patients follow-up and regular checkups [17-19]. In 
the present study we selected a large cohort of patients with T2D followed up at 90 diabetes centers in 
Italy among those participating in the Italian Association of Clinical Diabetologists (Associazione Medici 
Diabetologi, AMD) initiative. The analysis was performed using the data set of electronic medical records 
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collected between 1 January 2004 and 30 June 2011. For the purpose of the analysis, we considered only 
patients at least 18 years old and with a follow-up evaluation within 6 months complete for data about BP 
values, estimated glomerular filtration rate (eGFR), albuminuria and information on treatment.
Of 36, 302 patients identified, after exclusion of 33, 524 patients with a confirmed eGFR value above 60 
ml/min, or below 30 ml/min or missing information about medication, or lack of a diagnosis of hypertension 
(SBP <140 mm Hg and DBP <90mm Hg and not taking antihypertensive medications at baseline), a total of 2, 
778 patients from 84 clinics constitute the study population (Fig. 1). The centers involved in the study were 
homogeneously distributed throughout the country.
Study design
The analysis of the database is an attempt by the Italian Association of Clinical Diabetologists 
(Associazione Medici Diabetologi, AMD) initiative to identify a set of indicators that can be used in the 
context of continuous quality improvement. Participating centers adopted the same software systems for 
everyday management of outpatients, whereas a specially developed software package allowed us to extract 
the information we intended to analyze from all the clinical databases (AMD Data File). Moreover, data 
from all participating centers were collected and centrally analyzed anonymously [17-19]. All patients gave 
their informed consent and internal approval was obtained by the AMD annals Scientific Committee. The 
current initiative includes measuring and monitoring glycated hemoglobin (HbA1c), BP, LDL cholesterol 
(LDL-c), total and HDL cholesterol (HDL-c) and triglycerides. The use of specific classes of drugs was also 
evaluated. As normal ranges for HbA1c varied among centers, the percentage change with respect to the 
upper normal value (measured value/upper normal limit) was estimated and multiplied by 6.0 to allow 
comparisons among the centers. Kidney function was assessed by serum creatinine and urinary albumin 
excretion measurements. GFR was estimated for each patient using a standardized serum creatinine assay 
and the Chronic Kidney Disease Epidemiology Collaboration formula [20]. Increased urinary albumin 
excretion was diagnosed as: i. microalbuminuria if urinary albumin concentration was >30 and ≤300 mg/L, 
or if urinary albumin excretion rate was >20 and ≤200 μg/min, or if urinary albumin-to-creatinine ratio 
(ACR) was >2.5 mg/mmol in men and >3.5 mg/mmol in women and ≤30 mg/mmol in both gender; ii. 
macroalbuminuria if urinary albumin concentration was >300 mg/L, or if urinary albumin excretion rate 
was >200 μg/min, or if ACR was >30 mg/mmol in both gender. Albuminuria indicates patients with either 
micro or macroalbuminuria. At each participating center, all patients underwent physical examination and 
BP measurements according to a standardized protocol. BP was measured with the patient in the sitting 
position after a 5-min rest, with a mercury sphygmomanometer. SBP and DBP were read to the nearest 
2mmHg. Disappearance of Korotkoff sounds (phase V) was the criterion for DBP. Three measurements were 
taken at 2-min intervals, and the average value was used to define clinical SBP and DBP.
The main analysis was aimed at evaluating the association between aTRH, BP control and renal 
outcome during the study.  For each outcome, visits after the event occurrence were excluded from the BPC 
evaluation. The outcomes were: i) an eGFR reduction >30% from baseline and ii) worsening of albuminuria 
status
Definition of ATRH and BPC
We defined ATRH as SBP or DBP ≥ the BP goal while taking ≥3 antihypertensive medications including 
a diuretic or taking ≥4 antihypertensive medications including a diuretic regardless of BP values at baseline 
visit. The BP goal of <140/90 mm Hg used for this analysis is consistent with the recommended BP goal for 
patients with diabetes in recent guidelines [21-22].
Time-updated BP control (BPC) was defined as > 75% of visits with SBP and DBP <140/90 mmHg, 
while in secondary analyses time-updated mean SBP was analyzed as the average of all available SBP values 
before the occurrence of the endpoint if any. Patients not meeting the criteria for BPC were defined as 
uncontrolled.
Statistics
Data are given as mean values ± standard deviation (SD); categorical variables are described as 
frequencies and percentages. Data were analyzed by mixed models with diabetes clinics fitted as random 
effect considering patients as clusters of observations to take into account possible differences across 
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centres. Continuous variables were analyzed with a linear mixed regression model and categorical variables 
by using a mixed logistic regression model. Odds ratios (ORs) for each renal outcome were reported with 
their 95% confidence interval (95% CI). A multivariate model was fitted with a complete-case analysis 
performed including patients for which all data were observed. Assuming linearity of GFR reduction over-
time, its slope was taken as a measure of disease progression rate. For each patients, we calculated the 
regression coefficient (slope) of linear regression between eGFR value and the exact time in years from the 
first evaluation including all measurements from baseline to the 4-year visit. Cumulative incidence curves 
were created with the Kaplan-Meier method. A Cox proportional hazard model was used to derive hazard 
ratios (HRs) with 95% confidence intervals (CIs). The analyses were carried out using STATA software, 
Version 14 (StataCorp, College Station, Texas). P values of <0.05 were considered statistically significant.
Results
Among the 36, 302 patients evaluated annually over 4 years for arterial BP, eGFR and 
albuminuria, a confirmed prior eGFR value between 60 and 30 ml/min independently by 
albuminuria status, complete information about medications, and a diagnosis of hypertension, 
2, 778 patients have been selected for the present analyses (Fig. 1).
Overall, the mean age was 73±7 years, 50% of patients were men and the mean duration 
of diabetes was 15±10 years. The glycometabolic status of participants was fairly good, being 
the mean values of HbA1c and LDL-c of 7.3±1.3%, 107±33 mg/dl, respectively. The average 
BP was 144±19/79±9 mmHg, with 68% of patients showing either SBP or DBP values 
above 140/85 mmHg at the baseline visit. Ninety-one percent of patients were receiving 
antihypertensive treatment (with a mean of 2.4±1.4 drugs per patient), and 79% were 
taking an ACE-I or an ARB. Mean eGFR was 48±8 ml/min per 1.73m2 with 34% of patient 
with eGFR <45 ml/min and 36% of patients had increased albuminuria (Table 1).
The association between clinical and demographic factors and aTRH is shown in Table 
2. Higher BMI, lower eGFR and a more complex therapeutic strategy with aspirin and with 
antidiabetic drugs associated to insulin were independently associated with significantly 
higher odds of having aTRH. In addition, every 10 mL/min per 1.73 m2 decrease in GFR was 
associated with a 17% higher odds of ATRH (adjusted OR 1.17, CI 1.03-1.32; P=0.014)
The prevalence of aTRH was 32.7% (n=911). The baseline characteristics of patients 
with and without aTRH are also detailed in Table 1. Those with aTRH were more likely to be 
females, to have higher BMI, higher BP and lower low-density lipoprotein cholesterol levels 
than those without aTRH. Moreover, the former group had lower eGFR, with an increased 
prevalence of CKD3b and albuminuria, and higher serum uric acid levels.  As expected, 
patients with aTRH were more likely to be prescribed antihypertensive treatment (especially 
with diuretics and RAAS-inhibiting agents) and lipid-lowering treatment.
Fig. 1. Flow diagram 
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Table 1. Baseline characteristics of study patients and renal outcomes during the 4-year follow-up stratified 
by apparent resistant hypertension. Mean±SD or absolute frequency (percentage). ATRH, apparent resistant 
hypertension; BMI, body mass index; HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein 
cholesterol; LDL-c, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin converting enzyme-inhibitors; 
ARBs, angiotensin II receptor antagonists. Patients’ baseline missing data: known duration of diabetes in 
52 (1.9%), BMI in 173 (6.2%), serum uric acid in 1208 (43.5%), HbA1c in 50 (1.8%), total cholesterol in 
116 (4.2%), triglycerides in 158 (5.7%), HDL in 134 (4.8%), LDL in 184 (6.6%), and smoking status in 1107 
(39.8%). Worsening of albuminuria excluding patients with baseline macroalbuminuria. Serum uric acid 










Male sex 1376 (49.5%) 947 (50.7%) 429 (47.1%) 0.044 
Age (years) 73±7 73±7 73±7 0.538 
Known duration of diabetes (years) 15±10 14±10 15±10 0.225 
BMI (Kg/m2) 29.6±4.7 29.2±4.5 30.5±5.0 <0.001 
Serum creatinine (mg/dL) 1.32±0.25 1.31±0.24 1.33±0.26 0.115 
eGFR (mL/min/1.73 m2) 48±8 48±7 47±8 0.001 
eGFR 45-59.9 mL/min/1.73 m2 1837 (66.1%) 1266 (67.8%) 571 (62.7%) 0.019 
eGFR <45 mL/min/1.73 m2 941 (33.9%) 601 (32.2%) 340 (37.3%) 0.019 
Albuminuria 1006 (36.2%) 646 (34.6%) 360 (39.5%) 0.015 
Microalbuminuria 783 (28.2%) 507 (27.2%) 276 (30.3%) 0.110 
Macroalbuminuria 223 (8.0%) 139 (7.4%) 84 (9.2%) 0.114 
Serum uric acid (mg/dL) 6.2±1.5 6.0±1.5 6.4±1.5 <0.001 
Serum uric acid in the top gender-specific quintile 284 (18.1%) 162 (15.4%) 122 (23.4%) 0.001 
HbA1c (%) 7.3±1.2 7.3±1.2 7.3±1.2 0.496 
HbA1c≥7% 1550 (56.8%) 1032 (56.4%) 518 (57.7%) 0.738 
Total cholesterol (mg/dL) 186±39 187±39 185±38 0.105 
Triglycerides (mg/dL) 152±79 151±78 155±82 0.209 
Triglycerides ≥150 mg/dl 1064 (40.6%) 704 (39.8%) 360 (42.2%) 0.253 
HDL (mg/dL) 50±15 50±15 50±16 0.696 
HDL <40M <50F mg/dL 984 (37.2%) 655 (36.7%) 329 (38.2%) 0.515 
LDL (mg/dL) 107±33 108±33 105±33 0.031 
LDL ≥100 mg/dL 1465 (56.5%) 1011 (57.6%) 454 (54.0%) 0.155 
Systolic BP (mmHg) 144±19 142±19 148±19 <0.001 
Diastolic BP (mmHg) 79±9 79±9 80±9 0.008 
BP≥140/85 mmHg 1892 (68.1%) 1161 (62.2%) 731 (80.2%) <0.001 
Standard Deviation Systolic BP (mmHg) 13.5±6.5 13.2±6.4 14.0±6.7 0.005 
Standard Deviation Diastolic BP (mmHg) 6.6±3.6 6.6±3.6 6.5±3.5 0.508 
Non-proliferative retinopathy 422 (15.2%) 274 (14.7%) 148 (16.2%) 0.273 
Proliferative retinopathy 201 (7.2%) 130 (7.0%) 71 (7.8%) 0.387 
Smokers  147 (8.8%) 107 (9.5%) 40 (7.4%) 0.234 
Lipid-lowering treatment  1597 (57.5%) 1021 (54.7%) 576 (63.2%) 0.001 
Treatment with statins  1396 (50.3%) 879 (47.1%) 517 (56.8%) <0.001 
Treatment with fibrates  144 (5.2%) 105 (5.6%) 39 (4.3%) 0.096 
Antihypertensive treatment  2537 (91.3%) 1626 (87.1%) 911 (100.0%) - 
Treatment with ACE-Is/ARBs  2200 (79.2%) 1339 (71.7%) 861 (94.5%) - 
Aspirin  1185 (42.7%) 751 (40.2%) 434 (47.6%) 0.001 
Antidiabetic therapy     
Diet 121 (4.4%) 85 (4.6%) 36 (4.0%) 0.412 
Oral antidiabetic drugs 1447 (52.1%) 1002 (53.7%) 445 (48.8%) 0.020 
Oral antidiabetic drugs and insulin 545 (19.6%) 343 (18.4%) 202 (22.2%) 0.014 
Insulin 665 (23.9%) 437 (23.4%) 228 (25.0%) 0.404 
4-year outcome     
GFR reduction >30% 566 (20.4%) 351 (18.8%) 215 (23.6%) 0.007 
Worsening of albuminuria 999 (39.1%) 650 (37.6%) 349 (42.2%) 0.086 
Worsening of albuminuria to micro 642 (25.1%) 418 (24.2%) 224 (27.1%) 0.195 
Worsening of albuminuria to macro 357 (14.0%) 232 (13.4%) 125 (15.1%) 0.449 
Blood pressure control in at least 75% of visits     
BPC for eGFR red >30% 413 (14.9%) 312 (16.7%) 101 (11.1%) <0.001 
BPC for Albuminuria worsening 390 (15.3%) 294 (17.0%) 96 (11.6%) 0.001 
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Over the 4-year study follow-up, 20% 
of study patients (n=566) developed an 
eGFR reduction >30% from baseline and 
39% (n=999) a worsening in albuminuria 
status. Patients with aTRH showed a 
higher cumulative incidence for eGFR 
loss (HR 1.42, CI 1.19-1.69; P<0.001), as 
compared with those without aTRH (Fig. 
2 A and Fig. 3 A).
Baseline clinical features of patients 
grouped on the basis of achieved renal 
outcome within the study period are 
reported in Table 3. On average, patients 
who went on to develop an eGFR 
reduction >30% from baseline showed 
a worse clinical and metabolic profile. 
They had a longer duration of diabetes, 
higher BMI, triglycerides, and were more 
likely to be smokers, to be treated for 
hypertension and with insulin and to 
show macroalbuminuria and proliferative 
retinopathy. Moreover, they had higher 
HbA1c levels and BP values with a 
greater prevalence of aTRH and similar 
BPC despite a greater prevalence of 
antihypertensive and insulin treatment. 
On the other hand, those who went on 
to significantly increase albuminuria 
were more likely to be female and to 
show proliferative retinopathy, they 
had a longer duration of diabetes, lower 
Table 2. Multivariate analysis for apparent resistant hypertension. Factors Associated with Apparent 
Treatment Resistant Hypertension. Odds Ratio for single renal outcome with 95% confidence interval. 
eGFR, estimated glomerular filtration rate; BMI, body mass index; HbA1c, glycated haemoglobin; HDL-c, 
high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood 







Characteristics OR (95% CI) p 
Male sex 0.89 (0.74-1.08) 0.232 
Age (by 10 years) 1.03 (0.90-1.18) 0.688 
Duration of diabetes (by 1ß years) 0.97 (0.88-1.08) 0.609 
BMI (by 5 kg/m²) 1.34 (1.22-1.49) <0.001 
eGFR (by 10mL/min/1.73m² reduction 1.17 (1.03-1.32) 0.014 
Microalbuminuria 1.07 (0.87-1.33) 0.506 
Macroalbuminuria 1.21 (0.86-1.70) 0.270 
HbA1c≥7% 0.89 (0.73-1.09) 0.258 
Triglycerides ≥150 mg/dl 1.08 (0.88-1.31) 0.463 
HDL <40M <50F mg/dL 0.88 (0.72-1.07) 0.210 
LDL ≥100 mg/dL 0.88 (0.73-1.07) 0.200 
Non-proliferative retinopathy 1.00 (0.77-1.29) 0.987 
Proliferative retinopathy 1.03 (0.72-1.47) 0.873 
Lipid-lowering treatment  1.20 (0.99-1.46) 0.068 
Aspirin  1.24 (1.02-1.49) 0.029 
Antidiabetic therapy   
Diet 1.08 (0.68-1.71) 0.755 
Oral antidiabetic drugs 1.00  
Oral antidiabetic drugs and insulin 1.37 (1.06-1.76) 0.014 
Insulin 1.08 (0.84-1.39) 0.536 
 
Fig. 2. Cumulative incidence curves by Kaplan-Meier 
of eGFR reduction >30% from baseline on the basis 
of aTRH (A) and aTRH and BPC status (B) in patients 
with T2D. ATRH, apparent treatment resistant 
hypertension; eGFR, estimated glomerular filtration 
rate. Blood pressure control (BPC) refers to the 
proportion of visits with systolic and diastolic blood 
pressure <140/90 mm Hg.
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eGFR, higher uric acid and HbA1c levels 
and a lower prevalence of albuminuria at 
baseline as compared to those without 
albuminuria worsening. Moreover, they 
had similar BP levels and prevalence of 
aTRH and were less likely to show BPC. 
Blood pressure visit-to-visit variability 
was higher in the subgroup of patients 
who reached any renal endpoint within 
the study period (Table 1).
Additional analyses explored 
the relationship between different 
hypertension categories on the basis of 
aTRH and time updated BPC and renal 
outcomes. Individuals with uncontrolled 
aTRH showed a higher BMI and had 
higher BP values, HbA1c, and total, low-
density and high -density lipoprotein 
cholesterol levels than those with good 
BPC, with or without aTRH. On average, 
patients without time updated BPC 
showed lower eGFR values and were 
more likely to show albuminuria and in 
particular macroalbuminuria.  Patients 
with uncontrolled hypertension were less 
likely to be prescribed antihypertensive 
treatment (number of drugs 1.6±1.0 vs 
2.0±0.8 for no aTRH, p<0.001 and 3.8±0.9 
vs 4.2±0.7 for aTRH, p<0.001), aspirin and 
lipid-lowering treatment as compared to 
those with BPC (Table 4).
When we performed a multivariate analysis, only the presence of micro or 
macroalbuminuria and the prescription of antihypertensive treatment were significantly and 
independently associated to a loss of eGFR >30% from baseline as indicated in Table 5. At 
variance, male gender, age, low HDL, eGFR reduction and the presence of microalbuminuria 
and of retinopathy were significantly and independently associated to albuminuria 
worsening along the 4-year follow-up. Patients with aTRH and no BPC showed an increased 
risk of albuminuria progression as compared to those with no-aTRH and BPC (fully adjusted 
OR 1.53; CI 1.08- 2.18, P=0.017) (Table 5).
Moreover, patients with aTRH and BPC showed an increased risk of developing eGFR 
reduction as compared to those with no aTRH independently of the presence of BPC (fully 
adjusted HR 1.73; CI 1.1- 2.73 P=0.019 vs no aTRH and BPC and HR 1.88; CI 1.27- 2.78, 
P=0.002 vs no aTRH and no BPC, respectively) (Fig. 2 B). As for albuminuria worsening, 
patients with aTRH showed a higher risk (HR 1.15, CI 1.00-1.31; P=0.047), as compared 
with those without aTRH (Fig. 3 A). Patients with aTRH and no BPC showed a greater risk 
of albuminuria worsening as compared to those with aTRH and BPC (fully adjusted HR 1.6; 
CI 1.09- 2.39, P=0.018) as well as those with no aTRH independently of the presence of BPC 
(HR 1.47; CI 1.16- 1.86, P=0.001 and HR 1.19; CI 1.04-1.38, P= 0.015 for BPC and no BPC 
respectively) (Fig. 3 B).
We investigated changes in eGFR along the four year follow up on the basis of aTRH and 
BPC using adjusted mean values of eGFR slope. The yearly mean eGFR slope was significantly 
higher in patients with aTRH as compared to those without aTRH  (0.99 ±3.10 vs 0.55 ±3.20, 
Fig. 3. Cumulative incidence curves by Kaplan-Meier 
of albuminuria worsening on the basis of aTRH (A) 
and aTRH and BPC status (B) in patients with T2D. 
ATRH, apparent treatment resistant hypertension; 
Blood pressure control (BPC) refers to the proportion 
of visits with systolic and diastolic blood pressure 
<140/90 mm Hg.
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P=0.010). At variance, patients with and without BPC showed a very similar yearly mean 
eGFR slope (0.67 ±3.24 vs 0.70 ±3.17, P=0.698)
When our data were evaluated on the basis of time-updated mean SBP it emerged that 
aTRH patients showed a greater risk of developing low eGFR as compared to non aTRH 
patients over the entire range of BP (Fig. 4). Furthermore, while the risk for albuminuria 
worsening decreases along with BP reduction without reaching a nadir, the achievement of 
SBP values below 125 mmHg entails a paradoxical increase in the incidence of GFR reduction, 
thereby confirming the existence of a J curve relationship between SBP and renal function 
(Fig. 4 and 5).
Table 3. Baseline characteristics of study patients by renal outcome within 4-year. Mean±SD or absolute 
frequency (percentage). eGFR, estimated glomerular filtration rate; BMI, body mass index; HbA1c, glycated 
haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin converting enzyme-inhibitors; 















Male sex 1084 (49.0%) 292 (51.6%) 0.510 703 (45.2%) 524 (52.5%) <0.001 
Age (years) 73±7 73±8 0.916 73±7 73±7 0.099 
Known duration of diabetes (years) 14±10 16±10 0.005 14±10 15±10 0.015 
BMI (Kg/m2) 29.5±4.6 30.0±5.0 0.011 29.6±4.8 29.7±4.7 0.625 
Serum creatinine (mg/dL) 1.31±0.24 1.33±0.26 0.346 1.28±0.24 1.34±0.25 <0.001 
eGFR (mL/min/1.73 m2) 48±7 48±8 0.657 49±7 47±8 <0.001 
eGFR 45-59.9 mL/min/1.73 m2 1463 (66.1%) 374 (66.1%) 0.761 1079 (69.3%) 624 (62.5%) 0.004 
eGFR <45 mL/min/1.73 m2 749 (33.9%) 192 (33.9%) 0.761 477 (30.7%) 375 (37.5%) 0.004 
Albuminuria 726 (32.8%) 280 (49.5%) <0.001 534 (34.3%) 249 (24.9%) <0.001 
Microalbuminuria 610 (27.6%) 173 (30.6%) 0.129 534 (34.3%) 249 (24.9%) <0.001 
Macroalbuminuria 116 (5.2%) 107 (18.9%) <0.001 0 (0.0%) 0 (0.0%) - 
Serum uric acid (mg/dL) 6.1±1.5 6.3±1.6 0.029 6.0±1.5 6.3±1.6 0.010 
SUA in the top quintile 215 (17.3%) 69 (21.2%) 0.120 137 (15.7%) 121 (20.9%) 0.035 
HbA1c (%) 7.3±1.2 7.4±1.3 0.035 7.2±1.2 7.4±1.3 0.001 
HbA1c≥7% 1218 (56.1%) 332 (59.5%) 0.156 837 (55.0%) 583 (59.2%) 0.058 
Total cholesterol (mg/dL) 187±38 185±41 0.319 186±39 186±38 0.674 
Triglycerides (mg/dL) 150±78 160±84 0.021 149±78 152±77 0.609 
Triglycerides ≥150 mg/dl 828 (39.5%) 236 (44.9%) 0.061 567 (39.0%) 391 (41.3%) 0.289 
HDL (mg/dL) 50±15 50±16 0.642 51±15 50±15 0.228 
HDL <40M <50F mg/dL 780 (36.9%) 204 (38.3%) 0.394 534 (36.4%) 373 (39.1%) 0.226 
LDL (mg/dL) 108±33 105±35 0.095 107±33 107±32 0.688 
LDL ≥100 mg/dL 1180 (56.8%) 285 (55.1%) 0.548 808 (56.3%) 533 (56.7%) 0.571 
Systolic BP (mmHg) 143±19 145±20 0.004 143±19 144±19 0.463 
Diastolic BP (mmHg) 79±9 80±9 0.013 79±9 79±9 0.163 
BP≥140/85 mmHg 1494 (67.5%) 398 (70.3%) 0.078 1026 (65.9%) 681 (68.2%) 0.322 
Non-proliferative retinopathy 323 (14.6%) 99 (17.5%) 0.057 211 (13.6%) 166 (16.6%) 0.059 
Proliferative retinopathy 138 (6.2%) 63 (11.1%) <0.001 85 (5.5%) 84 (8.4%) 0.002 
Smokers  99 (7.4%) 48 (14.1%) <0.001 78 (8.4%) 57 (9.1%) 0.491 
Lipid-lowering treatment  1270 (57.4%) 327 (57.8%) 0.924 892 (57.3%) 568 (56.9%) 0.338 
Treatment with statins  1103 (49.9%) 293 (51.8%) 0.566 782 (50.3%) 489 (48.9%) 0.151 
Treatment with fibrates  124 (5.6%) 20 (3.5%) 0.048 77 (4.9%) 58 (5.8%) 0.359 
Antihypertensive treatment  1997 (90.3%) 540 (95.4%) 0.001 1420 (91.3%) 913 (91.4%) 0.586 
Treatment with ACE-Is/ARBs  1735 (78.4%) 465 (82.2%) 0.114 1220 (78.4%) 792 (79.3%) 0.679 
Aspirin  935 (42.3%) 250 (44.2%) 0.997 642 (41.3%) 436 (43.6%) 0.219 
Antidiabetic therapy       
Diet 107 (4.8%) 14 (2.5%) 0.019 70 (4.5%) 47 (4.7%) 0.606 
Oral antidiabetic drugs 1177 (53.2%) 270 (47.7%) 0.037 881 (56.6%) 484 (48.4%) <0.001 
Oral antidiabetic drugs and insulin 423 (19.1%) 122 (21.6%) 0.140 272 (17.5%) 224 (22.4%) 0.002 
Insulin 505 (22.8%) 160 (28.3%) 0.028 333 (21.4%) 244 (24.4%) 0.083 
       
Apparent resistant hypertension 696 (31.5%) 215 (38.0%) 0.007 478 (30.7%) 349 (34.9%) 0.109 
BPC in ≥75% of visits       
BPC for each outcome 325 (14.7%) 88 (15.5%) 0.929 264 (17.0%) 126 (12.6%) 0.006 
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Table 4. Baseline characteristics by apparent resistant hypertension and blood pressure control. Mean±SD 
or absolute frequency (percentage). ATRH, apparent resistant hypertension; BPC, > 75% of visits with SBP 
and DBP <140/90 mmHg. BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin converting enzyme-inhibitors; 
ARBs, angiotensin II receptor antagonists. The p values refer to the overall significance of logistic mixed 




















Male sex 163 (52.2%) 784 (50.4%) 57 (56.4%) 372 (45.9%) 0.085 
Age (years) 72±7 73±7 73±8 73±7 0.193 
Known duration of diabetes (years) 14±10 15±10 15±11 15±10 0.543 
BMI (Kg/m2) 28.8±4.4 29.3±4.6 28.8±4.3 30.7±5.0 <0.001 
Serum creatinine (mg/dL) 1.31±0.24 1.31±0.24 1.34±0.25 1.33±0.26 0.224 
eGFR (mL/min/1.73 m2) 49±7 48±7 48±8 47±8 0.001 
eGFR 45-59.9 mL/min/1.73 m2 209 (67.0%) 1057 (68.0%) 63 (62.4%) 508 (62.7%) 0.105 
eGFR <45 mL/min/1.73 m2 103 (33.0%) 498 (32.0%) 38 (37.6%) 302 (37.3%) 0.105 
Albuminuria 88 (28.2%) 558 (35.9%) 26 (25.7%) 334 (41.2%) <0.001 
Microalbuminuria 79 (25.3%) 428 (27.5%) 23 (22.8%) 253 (31.2%) 0.048 
Macroalbuminuria 9 (2.9%) 130 (8.4%) 3 (3.0%) 81 (10.0%) <0.001 
Serum uric acid (mg/dL) 6.1±1.6 6.0±1.4 6.3±1.5 6.4±1.5 <0.001 
Serum uric acid in the top quintile 38 (19.0%) 124 (14.6%) 13 (18.6%) 109 (24.2%) <0.001 
HbA1c (%) 7.2±1.3 7.3±1.2 7.2±1.1 7.4±1.2 0.258 
HbA1c≥7% 151 (49.8%) 881 (57.7%) 46 (46.0%) 472 (59.1%) 0.014 
Total cholesterol (mg/dL) 180±38 189±39 175±34 186±38 <0.001 
Triglycerides (mg/dL) 147±76 151±78 158±86 154±81 0.497 
Triglycerides ≥150 mg/dl 112 (37.1%) 592 (40.4%) 39 (40.2%) 321 (42.5%) 0.503 
HDL (mg/dL) 48±14 51±15 47±16 50±16 0.283 
HDL <40M <50F mg/dL 130 (42.8%) 525 (35.5%) 42 (42.4%) 287 (37.7%) 0.252 
LDL (mg/dL) 104±33 109±33 98±29 106±33 0.003 
LDL ≥100 mg/dL 157 (52.7%) 854 (58.7%) 46 (46.5%) 408 (55.1%) 0.059 
Systolic BP (mmHg) 125±12 145±19 129±15 150±18 <0.001 
Diastolic BP (mmHg) 75±8 80±9 75±8 81±9 <0.001 
BP≥140/85 mmHg 40 (12.8%) 1121 (72.1%) 29 (28.7%) 702 (86.7%) <0.001 
Non-proliferative retinopathy 48 (15.4%) 226 (14.5%) 18 (17.8%) 130 (16.0%) 0.644 
Proliferative retinopathy 16 (5.1%) 114 (7.3%) 5 (5.0%) 66 (8.1%) 0.140 
Smokers  24 (11.4%) 83 (9.0%) 8 (13.1%) 32 (6.6%) 0.170 
Lipid-lowering treatment  203 (65.1%) 818 (52.6%) 68 (67.3%) 508 (62.7%) <0.001 
Treatment with statins  178 (57.1%) 701 (45.1%) 62 (61.4%) 455 (56.2%) <0.001 
Treatment with fibrates  16 (5.1%) 89 (5.7%) 2 (2.0%) 37 (4.6%) 0.320 
Antihypertensive treatment  308 (98.7%) 1318 (84.8%) 101 (100.0%) 810 (100.0%) <0.001 
Treatment with ACE-Is/ARBs  246 (78.8%) 1093 (70.3%) 93 (92.1%) 768 (94.8%) <0.001 
Aspirin  146 (46.8%) 605 (38.9%) 52 (51.5%) 382 (47.2%) 0.012 
Antidiabetic therapy      
Diet 11 (3.5%) 74 (4.8%) 6 (5.9%) 30 (3.7%) 0.449 
Oral antidiabetic drugs 166 (53.2%) 836 (53.8%) 49 (48.5%) 396 (48.9%) 0.131 
Oral antidiabetic drugs and insulin 52 (16.7%) 291 (18.7%) 26 (25.7%) 176 (21.7%) 0.052 
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Table 5. Multivariate analysis for the occurrence of 4-year renal outcome. Odds Ratio for single renal 
outcome with 95% confidence interval. eGFR, estimated glomerular filtration rate; BMI, body mass index; 
HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein 
cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin converting 
enzyme-inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent resistant hypertension; 
BPC, > 75% of visits with SBP and DBP <140/90 mmHg. Complete-case analysis including 2312 patients 








Characteristics eGFR reduction >30% Albuminuria worsening OR (95% CI) p OR (95% CI) p 
Male sex 0.95 (0.75-1.19) 0.645 1.75 (1.43-2.14) <0.001 
Age (by 10 years) 1.04 (0.89-1.23) 0.613 1.18 (1.02-1.37) 0.025 
Duration of diabetes (by 10 years) 1.07 (0.95-1.21) 0.279 1.04 (0.94-1.16) 0.441 
BMI (by 5 Kg/m2) 1.11 (0.98-1.25) 0.091 1.05 (0.95-1.17) 0.329 
eGFR (by 10 mL/min/1.73 m2) 1.08 (0.93-1.25) 0.328 0.81 (0.71-0.92) 0.001 
Microalbuminuria 1.75 (1.35-2.26) <0.001 0.46 (0.37-0.58) <0.001 
Macroalbuminuria 5.64 (3.93-8.11) <0.001   
HbA1c≥7% 0.98 (0.77-1.26) 0.902 1.06 (0.86-1.31) 0.588 
Triglycerides ≥150 mg/dl 1.23 (0.97-1.56) 0.090 1.13 (0.92-1.40) 0.237 
HDL <40M <50F mg/dL 1.09 (0.86-1.39) 0.474 1.28 (1.04-1.58) 0.021 
LDL ≥100 mg/dL 0.93 (0.74-1.17) 0.557 1.19 (0.98-1.46) 0.085 
Non-proliferative retinopathy 1.17 (0.86-1.58) 0.325 1.42 (1.08-1.87) 0.011 
Proliferative retinopathy 1.56 (1.05-2.31) 0.027 1.90 (1.30-2.79) 0.001 
Lipid-lowering treatment 0.84 (0.66-1.06) 0.139 0.94 (0.77-1.16) 0.565 
Antihypertensive treatment 2.18 (1.18-4.02) 0.013 1.10 (0.69-1.74) 0.689 
Treatment with ACE-Is/ARBs 0.93 (0.66-1.31) 0.675 1.05 (0.77-1.41) 0.774 
Standard Deviation Systolic BP (mmHg) 1.00 (0.99-1.02) 0.630 1.01 (0.99-1.02) 0.468 
Standard Deviation Diastolic BP (mmHg) 1.03 (1.00-1.07) 0.078 1.02 (0.99-1.05) 0.300 
Aspirin 0.94 (0.74-1.18) 0.585 1.01 (0.82-1.24) 0.923 
Antidiabetic therapy     
Diet 0.84 (0.45-1.57) 0.590 1.28 (0.78-2.11) 0.329 
Oral antidiabetic drugs 1.00  1.00  
Oral antidiabetic drugs and insulin 1.02 (0.75-1.38) 0.908 1.36 (1.04-1.78) 0.025 
Insulin 0.95 (0.71-1.28) 0.748 1.21 (0.93-1.58) 0.151 
Group ATRH and BPC     
No ATRH and BPC 1.00  1.00  
No ATRH and No BPC 0.85 (0.59-1.23) 0.387 1.30 (0.94-1.81) 0.111 
ATRH and BPC 1.60 (0.90-2.85) 0.109 0.66 (0.37-1.18) 0.158 









Fig. 4. Odds Ratios with 
95% confidence interval of 
reaching eGFR reduction 
>30% from baseline on 
the basis of time-updated 
mean SBP in patients with 
and without aTRH. Patients 
were grouped into 10 
mmHg subsets (i.e. those 
between 136 and 144 in 
the group labelled 140 
and so on). The subset of 
patients with No-aTRH and 
140 mmHg SBP was taken 
as the reference group. 
ATRH, apparent treatment 
resistant hypertension.
 Kidney Blood Press Res 2018;43:422-438
DOI: 10.1159/000488255
Published online: March 20, 2018
© 2018 The Author(s). Published by S. Karger AG, Basel
www.karger.com/kbr 432
Viazzi et al.: ATRH BPC and CKD Progression in Patients with T2D
Discussion
This is, to our knowledge, the largest cohort study conducted so far to investigate the 
role of aTRH on renal disease progression in T2D patients with CKD.
The prevalence of aTRH we report here is higher than that recently recorded in the 
same Registry (33% vs 17%) in diabetic hypertensive patients with normal renal function. 
As expected, lower eGFR and higher BMI values are independently associated with aTRH. 
Our data are in keeping with those from the REGARDS study [23] and more recently from 
the CRIC study, showing that in CKD patients with T2D, the degree of GFR reduction is a 
major correlate/determinant of the presence of aTRH. In the present study, there was a 17% 
greater occurrence of aTRH for every 10 mL/min per 1.73 m2 reduction in eGFR. Moreover, 
in line with the hypothesis that aTRH is a typical feature of a high risk condition, patients 
with aTRH were more likely to be prescribed a greater and more articulated treatment 
including ASA and insulin.
One of the main findings of our study is that the presence of ATRH was independently 
related to a significantly greater risk of a eGFR loss >30% over the study period.
Recently, two large multicenter, prospective studies reported on the prognostic 
significance of resistant hypertension in CKD populations [24-25]. In the Masterplan study, 
de Beus et al. [24] evaluated 788 CKD patients (24% with diabetes) with a mean eGFR of 
38±15 mL/min per 1.73 m2. The prevalence of RH was 34% and nearly 27% of patients 
with RH reached end-stage renal disease showing during 5.3 years of follow-up. RH was 
associated with a 2.3-fold higher risk of end-stage renal disease and 1.5-fold higher risk for 
composite renal endpoint including death, initiation of dialysis or kidney transplantation.
Similarly, in the CRIC (Chronic Renal Insufficiency Cohort) Study the prevalence of aTRH 
was 40% among the 3367 CKD patients (52% with diabetes) with an eGFR of 20 to 70 mL/
min per 1.73 m2 [25]. Subjects with resistant hypertension had a poorer prognosis, and a 
28% higher risk of experiencing a renal complication (defined as 50% decrease in eGFR or 
renal transplantation or start of long-term renal dialysis) after 5 years of follow-up.
Despite some differences in the definition of RH, the above reported studies together 
with the present one consistently show that aTRH is a very frequent concomitant of CKD and 
entails an unfavorable renal outcome as compared to non aTRH.
A further, more innovative result of our study deals with the analysis of outcomes on the 
basis of different time-updated blood pressure levels.
Fig. 5. Odds Ratios with 
95% confidence interval 
of reaching the endpoint 
albuminuria worsening on 
the basis of time-updated 
mean SBP in patients with 
and without aTRH. Patients 
were grouped into 10 
mmHg subsets (i.e. those 
between 136 and 144 in 
the group labelled 140 
and so on). The subset of 
patients with No-aTRH and 
140 mmHg SBP was taken 
as the reference group. 
ATRH, apparent treatment 
resistant hypertension.
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Egan and coll. reported that in a large cohort of more than 100 000 hypertensive adults 
followed for a mean period of 3.9 years [15] those patients with aTRH who achieved tight BP 
control (as compared to usual one) showed an unfavourable CV outcome. These data were 
only partially confirmed by a more recent publication from the SMART study, conducted in 
hypertensive patients with clinically manifest vascular disease, wherein the Authors reported 
an increase in cardiovascular and all-cause mortality in association with aRH independently 
of BP control [26].
The present study is, to our knowledge, the first one to assess in a real world setting, 
the relationship between specific time-updated BP levels and renal progression in the 
presence or absence of aTRH. Our data show that while in patients without aTRH, achieving 
and maintaining recommended BP values over time does not impact on renal outcome, in 
the presence of RH a very tight time-updated blood pressure control is associated with a 
significantly worse renal prognosis.
Several RCTs have previously investigated the effect of different degrees of BP reduction 
on renal outcome in non-diabetic CKD patients with [27, 28] or without proteinuria [29]. 
More recently, the SPRINT trial, evaluated the effects of achieving a very tight SBP target 
(i.e. <120) or a standard one (i.e. <140 mmHg) on cardiovascular and renal outcomes over 
a 3-year follow-up period in a cohort of non-diabetic high risk individuals, including a large 
subgroup of CKD patients with minimal proteinuria. All these trials failed to show that 
achieving lower BP targets may provide reduction in eGFR decline or ESRD events, except 
for a post hoc analysis conducted in the subgroup of those with overt proteinuria.
As for patients with diabetes, the ACCORD BP trial included only a small number of 
individuals with CKD, therefore its results may have limited applicability to patients with 
renal impairment [30].
Thus, our data may provide new insights to understand the inconsistency of the 
paradoxical relationship between BP reduction and renal morbidity, the so called J curve 
phenomenon, which has been reported in some although not all previously published studies.
Our results support the hypothesis of a decreased tolerance to lower BP in subgroups at 
high vascular risk.  This may be the result of pathologic changes in vascular structure such as 
arteriolar endothelial dysfunction, hyaline arteriosclerosis and myointimal hyperplasia [31–
32], which lead to compromised vascular autoregulation and thus a limited ability to adapt to 
BP fluctuations [33]. As a matter of fact, a paradoxical increased in target organ morbidity at 
very low blood pressure levels is mostly observed in elderly patients and in individuals with 
comorbidities such as CKD, diabetes or atherosclerosis [34], clinical conditions well known 
for being associated with aTRH [15, 24]. (Figures 4A and B). Our data support the view that 
the lowest BP possible is not necessarily the optimal target for CKD patients although it is 
not possible to rule out some effect of reverse causality and suggest that de prescribing could 
be considered at least in a subset of patients.
Only a minority (i.e. about fifteen percent of the whole study group) of our patients 
could be defined as controlled according to our time-updated criteria, a rather disappointing 
figure which is in line with previous literature [35] and confirms the well-known notion 
that the reduction of renal function goes along with more severe hypertension.  From a 
clinical perspective these data call attention to the opportunity of intensifying BP lowering 
treatment, possibly with a greater use of diuretics to improve cardiovascular and renal 
outcome in this high-risk patients population as suggested by International Guidelines 
[20-21]. However, under an intensified therapeutic regimen most of these patients would 
automatically be reclassified as having aTRH, a condition which paradoxically entails a worse 
outcome. Both subgroups with/without aTRH show an increased renal risk at comparably 
high BP levels. While for many non aTRH patients with poorly controlled hypertension, up-
titration of treatment would translate into being re-classified as aTRH, at the same time 
it might bring about further reduction in BP (i.e. better therapeutic control and therefore 
better outcome). Thus, aTRH seems to represent a high risk condition, only partly modifiable 
by antihypertensive treatment.
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With regards to renal outcome, it is interesting to note that our study cohort, which was 
exclusively composed of diabetic patients with different degrees of proteinuria, showed a 
much faster rate of renal function deterioration than that recorded in non-diabetic mostly 
non proteinuric ckd patients participating in the SPRINT trial [36]. In fact, the yearly loss of 
mean eGFR recorded in our aTRH patients under real life clinical condition was (-0.99 ml/
min per 1.73 m2), a figure almost double than that observed in non aTRH patients (-0.55 
ml/min per 1.73 m2) and three times greater than what recorded in SPRINT in patients 
randomized to standard treatment (-0.32 ml/min per 1.73 m2). These findings once again 
emphasize that one should be cautious when extending (applying) results obtained from 
RCTs to different clinical phenotypes under “real-world” clinical settings.
A further important finding of the present study relates to the relationship between 
aTRH and changes in BP and albuminuria over time. We observed a trend toward greater 
albuminuria reduction in patients reaching the lowest BP values. These results are in 
line with those of previous studies [36, 37]. In fact, the group treated more intensively in 
the SPRINT study [36] had significantly lower urinary ACR levels throughout the follow-
up period, a finding consistent with results from the AASK trial [37], in which proteinuria 
decreased by 17% in the lower BP group and increased by 7% in the standard BP group.
We also recorded an association between reduction in albuminuria and lack of 
improvement or even faster deterioration in kidney function in patients with very tight 
BP control, a finding that casts some doubts on the usefulness of looking at changes in 
albuminuria as intermediate end point in renal outcome trials. While similar results have 
previously been reported in several intervention trials [38-40] our data should be taken with 
caution in this context as the observational nature of our study prevents us from establishing 
a cause-effect relationship. Nonetheless, we believe our results contribute to clarify the 
complex pathogenetic mechanisms underlying the renal function blood pressure relationship 
and point toward the need of defining individualized BP target at least in frail, comorbid 
patients, for whom the lower does not always means the better when it comes to BP levels. 
Furthermore, the modality (RAAS-inhibition, diuretics, anti-aldosteron, etc.) and the target 
of intervention to lower BP in patients with ATRH with the aim to improve cardiovascular 
and renal outcomes should be further investigated in future prospective studies.
Strength and Limitations
Our study has some limitations as well as several strengths that should be mentioned. 
Among the first ones, we must acknowledge that laboratory parameters, including serum 
creatinine, were not measured in a single, centralized laboratory and this may have led 
to some variability in GFR estimation. We did not gather information on specific dosage 
of antihypertensive medications prescribed to each patient to confirm diagnosis of aTRH. 
However, BP control significantly improved, on average, over the 4-year study period 
suggesting an attempt toward a therapeutic strategy of up-titration to maximum tolerated 
dose. We could not perform Ambulatory Blood Pressure Monitoring in our study patients 
and therefore we lack data about individual haemodynamic load and circadian BP behaviour. 
Furthermore, our data may not be applicable to the population with T2D, HT and CKD at 
large as the vast majority of participants were of white origin and ethnicity has previously 
been shown to bear some impact on the risk of developing renal complications [41]. Finally, 
we did not have information on extra-renal complications such as myocardial infarction and 
stroke, which may affect BP or renal function changes overtime. On the other hand, the large 
size and homogeneous clinical characteristics of study cohort as well as the representative 
geographical distribution of the recruiting centers and the relatively long follow-up period, 
do contribute to make our results a reliable representation of real-life clinical condition. 
Moreover, at variance with several previous studies on the impact of RH on CV and renal 
outcomes (10-15), we used a very accurate definition of RH, which included the use of 
diuretics.  Another strength of our work is the use of time-updated BP values as indicator of 
achievement and maintenance of blood pressure control over time.
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Conclusion
In patients with stage 3 CKD the presence of aTRH entails a faster loss of eGFR over a four-
year follow-up period. In patients with aTRH, achievement and maintenance of recommended 
BP values is associated with a worse renal prognosis despite greater albuminuria reduction. 
Thus, aTRH seems to be associated with a burden of risk modifiable only in part by 
BP reduction. Further studies are clearly needed to investigate the pathophysiological 
mechanism underlying the effect of BP reduction per se as well as different pharmacologic 
strategies on renal outcome in high risk hypertensive patients such as those with diabetes 
and CKD.
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